Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$45.57 USD

45.57
777,659

+1.27 (2.87%)

Updated Aug 27, 2024 03:59 PM ET

After-Market: $45.60 +0.03 (0.07%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Buy These 5 Low Leverage Stocks Amid Coronavirus-Led Sell Off

by Zacks Equity Research

This is a good time to go for safe stocks so that in the event of any further market turmoil the stockholders do not lose significantly. Stocks with low debt-to-equity ratio offer that safety.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strong domestic and international results for the fourth quarter of 2019.

Urmimala Biswas headshot

Tandem Diabetes Wins FDA's iAGC Designation for Basal-IQ

by Urmimala Biswas

Recent regulatory go-aheads for Tandem Diabetes' (TNDM) insulin pump systems anticipated to boost global pump shipments as well as expand its customer base.

Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Tandem Diabetes (TNDM) once again registers strong domestic pump shipment in Q4.

Zacks.com featured highlights include: International Money Express, Tandem Diabetes Care, Kirkland Lake Gold and USANA Health Sciences

by Zacks Equity Research

Zacks.com featured highlights include: International Money Express, Tandem Diabetes Care, Kirkland Lake Gold and USANA Health Sciences

4 Best-Ranked Liquid Stocks for Alluring Returns

by Zacks Equity Research

Four top-ranked liquid stocks that investors can bank on for fat returns.

Should You Buy Tandem Diabetes Care (TNDM) Ahead of Earnings?

by Zacks Equity Research

Tandem Diabetes Care (TNDM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?

by Zacks Equity Research

GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.

Sweta Killa headshot

5 Top-Ranked Stocks Beating the Market at Midway Q1

by Sweta Killa

Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.

Nalak Das headshot

5 High-Flying Stocks Set to Beat on Q4 Earnings Next Week

by Nalak Das

Fourth-quarter 2019 earnings results have been improving significantly.

What's in Store for SmileDirectClub's (SDC) Q4 Earnings?

by Zacks Equity Research

SmileDirectClub (SDC) is likely to have gained from a strong international presence in Q4.

Tandem Diabetes Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Tandem Diabetes (TNDM) is optimistic about maintaining growth momentum on several recent developments.

Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?

by Zacks Equity Research

Consistent contribution from Henry Schein One is likely to have benefited Henry Schein's (HSIC) Q4 performance.

Are Options Traders Betting on a Big Move in Tandem Diabetes (TNDM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Tandem Diabetes (TNDM) stock based on the movements in the options market lately.

Trina Mukherjee headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

by Trina Mukherjee

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Sonoco (SON) Meets Q4 Earnings Estimates

by Zacks Equity Research

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.

InMode (INMD) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

InMode's (INMD) Q4 performance is likely to have been driven by developments in business segments.

Medtronic (MDT) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.

Will Tandem Diabetes Care Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Tandem Diabetes.

Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?

by Zacks Equity Research

Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings

by Zacks Equity Research

Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter

Molina Healthcare (MOH) to Post Q4 Earnings: What to Expect

by Zacks Equity Research

Molina Healthcare's (MOH) fourth-quarter results are likely to reflect lower premium revenues and decline in medical membership.